Gemma Biotherapeutics (GEMMABio), the innovative gene therapy company spearheaded by renowned Philadelphia-based scientist Dr. Jim Wilson, is dramatically expanding its international footprint. In a landmark announcement, GEMMABio has officially sealed its second major international collaboration, further cementing its commitment to accelerate global access to life-changing genetic medicines for rare diseases. This significant momentum builds powerfully on the company’s strategic spin-out from the University of Pennsylvania’s world-renowned Gene Therapy Program, which Dr. Wilson expertly guided for over three decades, and the successful securing of a robust $34 million seed funding round last year.
This latest groundbreaking partnership sees GEMMABio joining forces with the Department of Health – Abu Dhabi (DoH), M42 (a global health champion powered by AI, technology and genomics), and PureHealth, recognized as the largest healthcare provider in the Middle East. This alliance, a testament to intense discussions at last month’s BIO International Convention 2025 in Boston, is designed to establish a formidable gene therapy ecosystem in the Middle East. Central to this collaboration will be the joint development of dedicated manufacturing and research centers within Abu Dhabi’s leading academic health institutions. This strategic infrastructure aims to provide patients from across the entire Middle East and North Africa (MENA) region with crucial access to cutting-edge clinical trials and, eventually, to approved gene therapies.
The initial clinical thrust of this exciting new venture will focus on a next-generation gene therapy product for children suffering from Spinal Muscular Atrophy type 1 (SMA Type 1). SMA Type 1 represents the most severe form of spinal muscular atrophy, a devastating rare genetic condition characterized by progressive muscle weakness and affecting critical motor skills. While existing therapies have made strides, the pursuit of “next-generation” treatments highlights GEMMABio’s commitment to continuous innovation in this field.
“Our partnership with GEMMABio marks a pivotal step in Abu Dhabi’s journey to become a global leader in developing gene therapies for rare diseases leveraging the Emirati Genome Programme,” stated Dr. Mohamed Alameri, Acting Director of Genome and Biobank Division at the Department of Health – Abu Dhabi. “At DoH, we are committed to reshaping innovation, early detection and personalised care by strengthening the Emirate’s capacity to develop, test and scale innovative therapeutics. Through these efforts, we are advancing life sciences applications while offering real hope to patients and families across the region and beyond.”
Dr. Jim Wilson, Founder, President, and CEO of GEMMABio, echoed this sentiment, stating: “This is a transformational partnership—one that will play a pivotal role in unlocking global access to life-saving treatments for patients with rare diseases. The stakeholders in Abu Dhabi are building a globally recognised gene therapy ecosystem whose impact on the future of life sciences will be both profound and far-reaching. Together, we are aligning scientific innovation with bold ambition to accelerate progress where it’s needed most.”
Crucially, these international partnerships represent a new, innovative approach to funding and running clinical trials in the gene therapy space. Rather than solely relying on traditional venture capital models, GEMMABio is forging direct collaborations with national health systems and governmental entities. This strategic pivot, exemplified by both the Abu Dhabi and Brazilian agreements, allows for a more integrated and potentially more sustainable pathway to bringing gene therapies to patients, particularly those in underserved populations, and at a potentially more affordable cost. “This partnership helps Abu Dhabi usher in another frontier in the future of health,” said Dimitris Moulavasilis, Group Chief Executive Officer of M42. “M42 is focused on developing genomic insights, fighting against rare diseases and saving lives. Our partnership with the Department of Health – Abu Dhabi and GEMMABio will accelerate this effort, ensuring people in the UAE and beyond get the gene therapies they need for longer, healthier lives.”
This new agreement significantly bolsters GEMMABio’s burgeoning international presence, serving as a powerful follow-up to its inaugural and highly impactful international collaboration forged in October 2024 with Brazil’s Oswaldo Cruz Foundation (Fiocruz). Fiocruz, a leading public health research institution and a vital component of the Brazilian Ministry of Health, committed a substantial sum of up to $100 million in funding under that agreement. This funding is dedicated to supporting clinical research and manufacturing efforts. The ambitious goal of the Brazil partnership is to facilitate the integration of gene therapy treatments into the country’s publicly funded healthcare system, Sistema Único de Saúde, thereby making these advanced therapies accessible to Brazil’s vast population of over 200 million people.
GEMMABio officially launched on October 1, 2024, a strategic move that followed Dr. Wilson’s departure from the University of Pennsylvania. His decision to spin out these critical research and development efforts was driven by a clear vision: to directly accelerate the translation of groundbreaking gene therapy discoveries from the lab bench into accessible, commercial-ready products for patients. The company’s impressive launch and rapid trajectory were further solidified by its $34 million seed funding round, announced in December 2024. This significant capital infusion brought in robust backing from a syndicate of leading investors, including Double Point Ventures, Bioluminescence Ventures, Earlybird Venture Capital, and Savanne Life Sciences, all of whom share GEMMABio’s ambitious vision.
The collaboration with M42 and GEMMABio also plans for a best-in-class gene therapy contract development and research manufacturing organization to be established in the Emirate as a joint venture. Additionally, regional access to GEMMABio’s commercialized gene products will be coordinated through Abu Dhabi’s gene therapy research and treatment centers. This is further supported by Abu Dhabi’s advanced infrastructure, forward-looking policies, and the Health, Endurance, Longevity and Medicine (HELM) Life Science Cluster, which offers streamlined licensing, co-commercialization processes, co-investment schemes, and tax relief for biotech startups, solidifying the Emirate’s position as a global hub for life sciences innovation. As H.E. Rashed Saif Al Qubaisi, Group Chief Operating Officer of PureHealth, emphasized, “This collaboration is a powerful reflection of Abu Dhabi’s growing influence as a global centre for health innovation. By joining forces with GEMMABio and our strategic partners, we are not only expanding access to advanced gene therapies, but also reinforcing the Emirate’s long-term commitment to solving some of the world’s most complex health challenges.”
For the vibrant Philadelphia biotech community, GEMMABio’s swift global expansion and innovative funding strategies underscore the enduring impact of local scientific leadership and the region’s pivotal role in the advancement of cutting-edge medical technologies. Dr. Wilson’s decades of pioneering work at Penn are now directly translating into tangible progress for patients on a global scale, solidifying Philadelphia’s standing as a critical hub for innovation in genetic medicines. We are extremely excited to see this unique funding and operational model unfold and demonstrate its potential to revolutionize access to these critical treatments worldwide.
